(Q33412690)

26 July 2017

title

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy (English)

1 reference

26 July 2017

1 reference

J R Berenson

1

1 reference

26 July 2017

J D Hilger

2

1 reference

26 July 2017

O Yellin

3

1 reference

26 July 2017

R Dichmann

4

1 reference

26 July 2017

D Patel-Donnelly

5

1 reference

26 July 2017

R V Boccia

6

1 reference

26 July 2017

A Bessudo

7

1 reference

26 July 2017

L Stampleman

8

1 reference

26 July 2017

D Gravenor

9

1 reference

26 July 2017

S Eshaghian

10

1 reference

26 July 2017

Y Nassir

11

1 reference

26 July 2017

R A Swift

12

1 reference

26 July 2017

R A Vescio

13

1 reference

26 July 2017

publication date

16 January 2014

1 reference

26 July 2017

1 reference

26 July 2017

volume

28

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

1529-1536

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

26 July 2017

copyright license

start time

16 January 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

1 reference

12 December 2020

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

1 reference

12 December 2020

CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma

1 reference

12 December 2020

Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland

1 reference

12 December 2020

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

12 December 2020

A note on quantifying follow-up in studies of failure time

1 reference

12 December 2020

A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma

1 reference

12 December 2020

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

1 reference

12 December 2020

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

1 reference

12 December 2020

Discovery and development of the anticancer agent salinosporamide A (NPI-0052).

1 reference

12 December 2020

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

1 reference

12 December 2020

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

1 reference

12 December 2020

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

1 reference

12 December 2020

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

1 reference

12 December 2020

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

1 reference

12 December 2020

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

1 reference

12 December 2020

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress

1 reference

12 December 2020

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

1 reference

12 December 2020

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

1 reference

12 December 2020

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

1 reference

12 December 2020

International uniform response criteria for multiple myeloma.

1 reference

12 December 2020

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

1 reference

12 December 2020

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

12 December 2020

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

1 reference

12 December 2020

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.27

1 reference

Dimensions Publication ID

26 July 2017

1009960903

0 references

1 reference